CellVir develops anti-retrovirals treatments focused on HIV-1 and the viral replication in infected cells.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Évry
State: Ile-de-France
Zip:
Country: France
CellVir, founded in March 2006, is developing a new generation of anti-retrovirals based on a novel therapeutic mode of action. Instead of targeting the inhibition of the catalytic activity of viral enzymes (as do most of today&s;s drugs), CellVir&s;s approach targets host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. Drugs operating via this novel mode of action offer two key potential advantages: complementarity to existing drugs because of their lack of susceptibility to cross resistance mechanisms, and a reduced occurrence of viral mutations that lead to drug resistance.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2008 | Venture Round | 2 | $387k |
Genopole Inserm Transfert Initiative Genopole Inserm Transfert Initiative |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|